- XORTX Therapeutics (XRTX) has announced the pricing of an underwritten public offering for gross proceeds of up to $5,000,000
- The offering consists of common share units and warrant and pre-funded warrant units
- Each common share unit consists of one common share and one warrant
- Each pre-funded warrant is exercisable to purchase one common share and one warrant
- The offering is expected to close on or about October 6, 2022
- XORTX is a pharmaceutical company
- XORTX Therapeutics Inc. (XRTX) opened trading at C$1.66
XORTX Therapeutics (XRTX) has announced the pricing of an underwritten public offering for gross proceeds of up to $5,000,000.
The offering consists of common share units and pre-funded warrant units Each common share unit consists of one common share and one warrant.
Each warrant is exercisable to purchase one common share at a public offering price of US$1.00. Each pre-funded warrant unit consists of one pre-funded warrant to purchase one common share and one warrant to purchase one common share.
Each pre-funded warrant is exercisable to purchase one common share and one warrant. Each warrant is exercisable to purchase one common share at a public offering price of US$0.9999.
The offering is expected to close on or about October 6, 2022.
XORTX is a pharmaceutical company with two clinically advanced products in development.
XORTX Therapeutics Inc. (XRTX) opened trading at C$1.66.
